Mepolizumab attenuates ILC2s proliferation and activity in adults with severe eosinophilic asthma

Respirology. 2023 Aug;28(8):696-698. doi: 10.1111/resp.14517. Epub 2023 May 10.
No abstract available

Keywords: asthma; clinical allergy and immunology; cytokine; eosinophil; inflammation.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Adult
  • Anti-Asthmatic Agents* / pharmacology
  • Anti-Asthmatic Agents* / therapeutic use
  • Asthma* / drug therapy
  • Cell Proliferation
  • Eosinophils
  • Humans
  • Immunity, Innate
  • Lymphocytes
  • Pulmonary Eosinophilia* / drug therapy

Substances

  • mepolizumab
  • Anti-Asthmatic Agents